Treatment with liver X receptor (LXR) agonists like benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide], or more commonly known as T0901317 (T09), lowers the cholesterol level in serum and liver and inhibits the development of atherosclerosis in murine disease models. T09 modulates cholesterol metabolism and inhibits inflammation.
